KRYS — Krystal Biotech, Inc.

Is KRYS overbought or oversold? Here is the current MarketMoodz read.

Healthcare · Biotechnology

Oversold As of October 3, 2026

Krystal Biotech, Inc. (KRYS) currently reads Oversold on the MarketMoodz overbought/oversold meter, as of October 3, 2026. The Healthcare name (Biotechnology) last closed at $322.28. The rating moved from Neutral to Oversold on October 1, 2026.

See all oversold Healthcare stocks →

AI analysis

Krystal Biotech, Inc. is a specialized biotech whose near-term trajectory is driven by clinical and regulatory catalysts plus the company’s cash runway. Sector-level support for select late-stage biologics and occasional high-conviction insider or specialist buying can provide episodic upside, but a broader risk-off market, pricing policy headwinds, and typical small‑cap funding sensitivity keep the stock volatile. Investors should monitor upcoming clinical milestones, balance-sheet disclosures, and payer/regulatory developments to reassess upside potential and dilution risk.

Key factors

  • Small-cap specialty biotech with focus on targeted biologic/gene-therapy modalities that attract episodic investor interest tied to clinical readouts
  • Sector tailwind for select late-stage biologics and visible insider/specialist conviction supports valuation and funding optionality
  • Market-wide risk-off tone and light volumes have reduced appetite for smaller, higher-volatility healthcare names in the near term
  • Policy pressure on drug pricing and Medicare negotiation increases uncertainty around future pricing, access and reimbursement
  • Liquidity and funding cadence are a primary driver for near-term upside or downside given typical biotech cash burn profiles
  • Potential upcoming clinical or regulatory catalysts (trial updates, filings) could materially re-rate the stock in either direction

Risks

  • Clinical trial failure or disappointing data that would directly damage the core commercial/clinical thesis
  • Regulatory setbacks or delays that push milestones and increase cash needs
  • Adverse shifts in payer coverage or pricing (Medicare negotiation / IRA-related policy actions) that reduce expected revenues
  • Funding/dilution risk if cash runway is insufficient and capital must be raised in an unfavorable market
  • Market risk: continued risk-off environment and low liquidity can exaggerate downside moves
  • Manufacturing, supply-chain or commercialization execution problems that impede launch or scale-up

See today's live rating, score and targets

Members see the live hourly rating for KRYS — the numeric AI score plus targets and entry zones — while this public page updates nightly.

Start the 14-day trial

This page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.